Recombinant Interleukin-1 Receptor antagonist is an effective first-line treatment strategy in new-onset systemic Juvenile Idiopathic Arthritis, irrespective of HLA-DRB1 background and IL1RN variants.
Remco G A ErkensJorg J A CalisAnouk VerwoerdSytze De RoockNienke M Ter HaarGerda Den EngelsmanLars T Van der VekenRobert F ErnstHanneke W M Van DeutekomAlex PickeringRianne C ScholmanMarc H A JansenJoost F SwartRashmi SinhaJohannes RothGrant S SchulertAlexei A GromJorg Van LoosdregtSebastiaan J VastertPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
We observed high rates of CID using anakinra as first-line treatment irrespective of HLA-DRB1 or IL1RN variants. Only one of the 17 HLA-DRB1*15:01 carriers developed sJIA-LD, and of the 3 patients with drug reactions to biologics, only one carried HLA-DRB1*15:01. Although thorough monitoring for the development of drug hypersensitivity and refractory disease courses in sJIA, including sJIA-LD remains important, our data support the early start of biological therapy in new-onset sJIA patients irrespective of HLA-DRB1 background or IL1RN variants.
Keyphrases
- juvenile idiopathic arthritis
- copy number
- end stage renal disease
- ejection fraction
- newly diagnosed
- drug induced
- chronic kidney disease
- emergency department
- prognostic factors
- stem cells
- big data
- bone marrow
- machine learning
- disease activity
- systemic lupus erythematosus
- dna methylation
- mesenchymal stem cells
- cell free
- genome wide
- patient reported
- replacement therapy
- data analysis